Kiromic BioPharma Inc (KRBP) 銘柄情報

KRBP

Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial

https://www.otcmarkets.com/stock/KRBP/news/Kiromic-BioPharma-Reports-Favorable-10-Month-Follow-Up-Results-for-the-First-Patient-Treated-in-its-Deltacel-01-Clinical?id=454504

KRBP...........................https://stockcharts.com/h-sc/ui?s=KRBP&p=W&b=5&g=0&id=p86431144783

KRBP....................https://stockcharts.com/h-sc/ui?s=KRBP&p=W&b=5&g=0&id=p86431144783

Chap 11 likely.

Big time.

Seriously big time!!!!

It DUMPED

What the hell happened to KRBP?

From over $20 to fifty cents in less than a year.........

KRBP delisted from the Nasdaq to the OTC. PPS dropped 56% to .69 in after hours.

https://otce.finra.org/otce/dailyList?viewType=Additions

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14

Kiromic Biopharma Inc NASDAQ: KRBP*

GoSymbol lookup



*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Kiromic BioPharma, Inc. is an artificial intelligence (AI) driven, end-to-end allogenic cell therapy company. The Company is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.

Out for the time being

see how long it lasts on the announcement at least got news this time.

KRBP: Its 68% price uptick right now in the A.H., has my new DDAmanda-Price-Prognosticator blowing fuses!!! (See below!!)

in the red now fun while it lasted looking for another entry gl.

Wild

KRBP...................................https://stockcharts.com/h-sc/ui?s=KRBP&p=W&b=5&g=0&id=p86431144783

There she goes

5.20's nice pull that crazy move next week biatch

going again

hit 4.80 :) took some of table, i wanna see this to the crazy run lol.

nice chomp chomp

Big block

$KRBP $5+ explosion yesterday but I guess the company is now worth less after IND news...this small cap market is a complete joke controlled and owned by naked shorts. I bought a ton today. Good luck to all.

https://ih.advfn.com/stock-market/NASDAQ/kiromic-biopharma-KRBP/stock-news/90675566/kiromic-biopharma-submits-investigational-new-drug

If this can break 5.11 vatch out then. Kimchi got the memo from Brudge Netvorks

Fun day

Wow, someone's stop loss got taken out. Now let's see what happens.

KRBP inturusting here.

My key words are these -->

Favorable Safety Results are Last Component Needed to Complete the Nonclinical Module of the Company's IND Application

Does this $hitty stock action make sense? Hell no who can argue that?
However this is when you load up and wait until PH1 because that was dang good news for an emerging bio startup with AI tech that treats LUNG CANCER tumors >> JMHO << but I've done a ton of DD on this just wait a storm is coming...

IND Submission and Activation of Clinical Trial Process on Track for the First Quarter and Second Quarter of this Year, Respectively

Kiromic BioPharma, Inc.

The histopathology report, authored by a certified veterinary pathologist, revealed no adverse microscopic findings related to the administration of Deltacel™ alone or as part of the combination treatment.

"We're pleased to receive a clean pharmacology profile with no adverse findings and are encouraged by the preclinical results to-date in support of our planned IND submission. This histopathology report includes results from more than 500 histological sections from multiple organs of mice treated with Deltacel™, with the combination treatment of Deltacel™ and a non-biological anti-tumor therapy, or mice left untreated. This study completes the necessary dataset for authoring the Pharmacology Report of the Efficacy Study, which is an essential component of the nonclinical module of our IND application," stated Leonardo Mirandola, Ph.D., Chief Scientific Officer of Kiromic BioPharma.

"These findings are in line with what we observed in a study evaluating Deltacel™ monotherapy at a dose more than 7 times higher than the maximum dose planned for the Deltacel™ clinical trial, and they confirm that Deltacel™ was well tolerated in mice, even when given as part of a combination therapy that further boosted its potency," continued Dr. Mirandola. "Kiromic plans to submit the Deltacel™ IND application to the U.S. FDA in this first quarter, and if accepted, plans to begin the activation of the clinical trial process in the second quarter of 2023. The planned clinical study will evaluate Deltacel™ in combination with a non-biological anti-tumor therapy for the treatment of non-small cell lung cancer."

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to detect, develop, and commercialize cell therapies with a therapeutic focus on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid cancers. Kiromic's DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

https://www.businesswire.com/news/home/20230228005440/en/Kiromic-BioPharma-Reports-Favorable-Deltacel%E2%84%A2-Preclinical-Pharmacology-Results

KEY WORD: PRE-CLINICAL

NOT EVEN PHASE 1

FLOAT LOOKS SMALL

https://finance.yahoo.com/news/kiromic-biopharma-arranges-10-million-124800993.html

$KRBP nice news out this could squeeze over .50

https://www.benzinga.com/pressreleases/23/02/b31089226/kiromic-biopharma-reports-favorable-deltacel-preclinical-pharmacology-results

KRBP................................https://stockcharts.com/h-sc/ui?s=KRBP&p=W&b=5&g=0&id=p86431144783

Is there news Monday I hope we see .50

what happened ah?

Keep on watch list.. This one will have it's day.

Keep on watch list.. This one will have it's day.

.40 next stop.

Microsoft ai roll out tomorrow...Google ai roll out wed.

Sleep well.dream big.

Chasing will start pre-market. Watch big buys roll in. .28 will be breached pre-market.

I think we nailed it at right price,right time.

$KRBP super close hoping for a multi-bagger here $$

It wants to go. Moves easily.

Exactly what I paid.

I jumped back in at .23. Good timing. Or lucky timing.

Heating up

accumulation @ 90day high,loading and holding started jan 20th,couple of flippers now posting unknown analysts' negative opinions smh,trying to flip a low float for a few pennies when thats the spread,oooops lol,newbies smh

KRBP.......https://stockcharts.com/h-sc/ui?s=KRBP&p=W&b=5&g=0&id=p8643114478

parabolic again,gotta love it

.24 demand building/new support,double bounce,reloading now

shares available to short dropped 700% today,float getting locked up,going to 0 shortable could put a nice squeeze on KRBP